New drug combo tested to fight spreading kidney cancer
NCT ID NCT01684397
Summary
This study is testing a combination of two drugs, pazopanib and bevacizumab, for people with advanced kidney cancer that has spread. The main goals are to find the safest and most effective dose and to see how well the treatment works to control the cancer and stop it from getting worse. It is for adults with a specific type of kidney cancer who have not yet received treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karamanos Cancer Institute
Detroit, Michigan, 482018, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
The University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.